Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying ART0380, an investigational oral drug that targets ATR kinase, in people with advanced or metastatic solid tumors, including ovarian, peritoneal, fallopian tube, endometrial, colorectal, pancreatic, and acinar cell cancers. This open-label Phase IIIa trial aims to find the recommended dose of ART0380 alone and in combination with gemcitabine or irinotecan, to understand its side effects, and to evaluate its preliminary effectiveness in treating cancers that may have DNA repair defects or loss of ATM protein expression. Participants may receive ART0380 either alone or combined with gemcitabine or irinotecan in 21-day treatment cycles. ART0380 is given orally either intermittently or continuously, while gemcitabine is given on days 1 and 8, and irinotecan is infused on days 1 and 8 of each cycle. The study has multiple parts, including dose escalation phases and expansion cohorts targeting specific cancer types or genetic profiles. Some parts compare ART0380 plus gemcitabine to gemcitabine alone, while others explore ART0380 with irinotecan or as monotherapy. Throughout the study, participants will undergo regular assessments including imaging scans to evaluate tumor response by RECIST criteria, blood tests for tumor markers, and safety monitoring for side effects. Pharmacokinetics of ART0380 will be measured to understand drug levels and metabolism. Follow-up for progression-free survival and overall survival will continue for up to two years or more. Participants are expected to adhere to study visits and procedures, with performance status and organ function closely monitored during the trial.
Actively Recruiting
Researchers are studying ATTR-01, an experimental drug made from a modified common cold virus designed to infect and multiply only in cancer cells. This virus carries an immune therapy drug aimed at helping a participants own immune system target cancer. The trial includes a phase 1 dose escalation and expansion to find the best dose, marking the first time ATTR-01 will be given to humans. If an optimal dose is found, further study sub-protocols will evaluate its potential to treat select epithelial solid tumors. Participants receive ATTR-01 through intravenous injection. The study starts with a phase 1 segment focusing on dose finding and safety. If successful, additional phases may be added to further assess the drugs effect on cancer. The trial includes one experimental group receiving ATTR-01, with no placebo or control group. Expanded access to ATTR-01 outside the trial is not available. During the study, participants will have evaluations including tumor measurements by RECIST version 1.1 criteria, biopsies before and after treatment, and assessments of organ function and immune response. Researchers will monitor safety by tracking adverse events and will measure outcomes like tumor response, disease control, progression-free survival, and overall survival at 1, 2, and 5 years. The trial also evaluates viral persistence and immunogenicity. Participants are expected to comply with hygiene measures to prevent virus spread, and the study follows them for up to several years.
Actively Recruiting
Researchers are evaluating OTP-01, a dual paratopic PD-1VEGFR2 antibody, in adults with advanced solid tumors to determine the best dose, understand how it is tolerated, and identify any side effects. The study also aims to see whether OTP-01 can shrink tumors and how the body processes the drug by measuring its levels in the blood. This trial is a Phase 12A study led by Ottimo Pharma Limited. Participants receive OTP-01 through an intravenous infusion, with doses spaced out and given no more than once a week. The study includes a dose escalation phase and a dose expansion phase, where participants may also opt for tumor biopsies before and after treatment to help researchers understand the drugs effects on cancer and the immune system. Tumor scans are done at the start and regularly during the study to monitor changes. During the trial, participants undergo frequent blood tests initially to check safety and drug levels, which become less frequent over time. Researchers measure adverse events, tumor responses, and progression-free survival up to 36 months. Optional tumor biopsies are voluntary and do not affect participation. The total study duration can be up to three years, with ongoing monitoring of safety and effectiveness throughout.
Actively Recruiting
Researchers are evaluating JK06, a biparatopic anti-5T4 antibody drug conjugate, in patients with unresectable locally advanced or metastatic solid tumors. This Phase 12, open-label study aims to assess the safety, tolerability, pharmacokinetics, immunogenicity, and initial anti-tumor activity of JK06. The study includes dose escalation to find the maximum tolerated dose and recommended Phase 2 dose, followed by dose expansion in specific tumor groups to further evaluate safety and early efficacy. Participants receive JK06 intravenously in cycles of 21 days. The dose escalation phase involves increasing doses to identify the optimal dose, while the cohort expansion phase uses this dose to treat tumor-specific groups. The study is randomized without masking and includes multiple centers. Treatment continues through these phases to collect detailed safety and response data. During the study, participants will have regular assessments including tumor measurement by CT or MRI scans, laboratory tests to monitor blood counts and organ function, and evaluations of adverse events. Researchers will track dose-limiting toxicities, pharmacokinetics, immune response, and tumor response over up to 104 weeks. Participants are monitored for safety up to 28 days after the last dose, and long-term outcomes such as progression-free survival and duration of response are also recorded.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of PC14586 rezatapopt, an oral drug designed to reactivate the p53 protein specifically for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation. This Phase 12 study includes a Phase 1 portion assessing safety, tolerability, and early effects of various doses of rezatapopt alone and combined with pembrolizumab, as well as a Phase 2 portion focusing on the drugs efficacy and safety at the recommended dose in different cancer types. Participants receive daily oral doses of rezatapopt, with dose levels adjusted to find the maximum tolerated dose and recommended Phase 2 dose. Some participants receive rezatapopt alone, while others receive it combined with pembrolizumab given intravenously every three weeks. Expansion groups include patients with different tumor types such as ovarian, lung, breast, and endometrial cancers, all harboring the TP53 Y220C mutation. The study monitors participants over several months to evaluate response rates and safety. Throughout the study, participants undergo regular assessments including imaging to measure tumor response according to RECIST criteria, blood tests to study drug levels and safety, and quality of life questionnaires. Safety is closely monitored by tracking adverse events. The total study duration varies but includes extended follow-up of up to 34 months in Phase 2. The trial is non-randomized and open-label, allowing researchers to gather detailed information on the drugs effects in this patient population.